1. Widimsky J Jr, Strauch B, Petra´k O, Rosa J, Somloova Z, Zelinka T, Holaj R. Vascular disturbances in primary aldosteronism: clinical evidence. Kidney Blood Press Res. 2012;35(6):529–533.
2. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8): 1243–1248.
3. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168(1):80–85.
4. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, Tiberio GA, Giulini SM, Agabiti-Rosei E, Pessina AC. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension. 2008;51(5):1366–1371.
5. Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens. 1995;13(12 Pt 2):1801–1802.
6. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM; Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9): 3266–3281.
7. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293–2300.
8. Rossi GP, Seccia TM, Pessina AC. Primary aldosteronism—part I: prevalence, screening, and selection of cases for adrenal vein sampling. J Nephrol. 2008;21(4):447–454.
9. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5): 607–618.
10. Stowasser M, Gordon RD. Primary aldosteronism. Best Pract Res Clin Endocrinol Metab. 2003;17(4): 591–605.
11. Nishikawa T, Saito J, Omura M. Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating hypertensive patients with medication? Endocr J. 2007;54(4):487–495.
12. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193–202.
13. Omura M, Sasano H, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 pa- tients with primary aldosteronism. Hypertens Res. 2006;29(11):883–889.
14. Okamura T, Nakajima Y, Katano-Toki A, Horiguchi K, Matsumoto S, Yoshino S, Yamada E, Tomaru T, Ishii S, Saito T, Ozawa A, Shibusawa N, Satoh T, Okada S, Nagaoka R, Takada D, Horiguchi J, Oyama T, Yamada M. Characteristics of Japanese aldosterone-producing adenomas with KCNJ5 mutations. Endocr J. 2017;64(1):39–47.
15. Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N, Ozawa A, Okada S, Rokutanda N, Takata D, Koibuchi Y, Horiguchi J, Oyama T, Takeyoshi I, Mori M. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab. 2012;97(4):1311–1319.
16. Yamada M, Nakajima Y, Taguchi R, Okamura T, Ishii S, Tomaru T, Ozawa A, Shibusawa N, Yoshino S, Toki A, Ishida E, Hashimoto K, Satoh T, Mori M. KCNJ5 mutations in aldosterone- and cortisol-co- secreting adrenal adenomas. Endocr J. 2012;59(8):735–741.
17. Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, Mulatero P, Samson-Couterie B, Hahner S, Quinkler M, Fallo F, Letizia C, Allolio B, Ceolotto G, Cicala MV, Lang K, Lefebvre H, Lenzini L, Maniero C, Monticone S, Perrocheau M, Pilon C, Plouin PF, Rayes N, Seccia TM, Veglio F, Williams TA, Zinnamosca L, Mantero F, Benecke A, Jeunemaitre X, Reincke M, Zennaro MC. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hy- pertension. 2012;59(3):592–598.
18. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295(22):2638–2645.
19. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S; Participants of German Conn’s Registry. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab. 2009;94(3):869–875.
20. Iwakura Y, Morimoto R, Kudo M, Ono Y, Takase K, Seiji K, Arai Y, Nakamura Y, Sasano H, Ito S, Satoh F. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab. 2014;99(5): 1593–1598.
21. Utsumi T, Kawamura K, Imamoto T, Nagano H, Tanaka T, Kamiya N, Nihei N, Naya Y, Suzuki H, Ichikawa T. Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy. Int J Urol. 2013; 20(7):685–691.
22. Tsurutani Y, Sugisawa C, Ishida A, Inoue K, Saito J, Omura M, Nagasaka S, Nishikawa T. Aldosterone excess may inhibit insulin secretion: a comparative study on glucose metabolism pre- and post- adrenalectomy in patients with primary aldosteronism. Endocr J. 2017;64(3):339–346.
23. Miura K, Okuda N, Turin TC, Takashima N, Nakagawa H, Nakamura K, Yoshita K, Okayama A, Ueshima H; NIPPON DATA80/90 Research Group. Dietary salt intake and blood pressure in a rep- resentative Japanese population: baseline analyses of NIPPON DATA80. J Epidemiol. 2010;20(suppl 3):S524–S530.
24. Nakajima Y, Yamada M, Taguchi R, Satoh T, Hashimoto K, Ozawa A, Shibusawa N, Okada S, Monden T, Mori M. Cardiovascular complications of patients with aldosteronism associated with autonomous cortisol secretion. J Clin Endocrinol Metab. 2011;96(8):2512–2518.
25. Gakkai NJ. [Special issue: Evidence-based practice guideline for the treatment of CKD]. Nippon Jinzo Gakkai Shi. 2013;55(5):585–860.
26. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, Hurt DE, Lin L, Xekouki P, Stratakis CA, Chrousos GP. A novel point mutation in the KCNJ5 gene causing primary hyper- aldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab. 2012; 97(8):E1532–E1539.
27. Ministry of Health, Labour and Welfare, Japan. The National Health and Nutrition Survey in Japan, 2016 (in Japanese).
28. Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, Hishida A, Matsuo S. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31(3):433–441.
29. Catena C, Colussi G, Sechi LA. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era. Eur J Endocrinol. 2012;168(1):C1–C5.
30. Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldoste- ronism: outcomes after treatment. Am J Hypertens. 2010;23(12):1253–1260.
31. Kim DH, Kwon HJ, Ji SA, Jang HR, Jung SH, Kim JH, Kim JH, Lee JE, Huh W, Kim YG, Kim DJ, Oh HY. Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with pri- mary aldosteronism. Medicine (Baltimore). 2016;95(27):e3930.
32. Kramers BJ, Kramers C, Lenders JW, Deinum J. Effects of treating primary aldosteronism on renal function. J Clin Hypertens (Greenwich). 2017;19(3):290–295.
33. Choi M, Scholl UI, Yue P, Bjo¨ rklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, A˚kerstro¨ m G, Wang W, Carling T, Lifton RPK. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331(6018):768–772.
34. Song KH, Park JI, Lee MO, Soh J, Lee K, Choi HS. LH induces orphan nuclear receptor Nur77 gene expression in testicular Leydig cells. Endocrinology. 2001;142(12):5116–5123.
35. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Palumbo G, Patalano A, Rizzoni D, Rossi E, Pessina AC, Mantero F; Primary Aldoste- ronism Prevalence in Hypertension Study Investigators. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab. 2008; 93(7):2566–2571.
36. Somlo´ova´ Z, Widimsky´ J Jr, Rosa J, Wichterle D, Strauch B, Petra´k O, Zelinka T, Vlkova´ J, Masek M, Dvora´kova´ J, Holaj R. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. J Hum Hypertens. 2010;24(10):625–630.
37. Weiner ID, Wingo CS. Hypokalemia: consequences, causes, and correction. J Am Soc Nephrol. 1997; 8(7):1179–1188.
38. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 1964;107(1):159–172.
39. Sambrook MA, Heron JR, Aber GM. Myopathy in association with primary hyperaldosteronism. J Neurol Neurosurg Psychiatry. 1972;35(2):202–207.
40. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
41. Grupo de Trabajo de la SEC sobre la guı´ a de hipertensio´n arterial ESC/ESH 2013, revisores expertos de la guı´ a de hipertensio´n arterial ESC/ESH 2013 y Comite´ de Guı´ as de Pra´ctica Clı´ nica de la SEC. Comments on the ESC/ESH guidelines for the management of arterial hypertension 2013. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed). 2013;66(11):842–847.
42. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S; Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension guidelines for the man- agement of hypertension (JSH 2014). Hypertens Res. 2014;37(4):253–390.
43. Imai E, Abe K. Blood pressure drop in summer may cause acute kidney injury with irreversible re- duction of glomerular filtration rate. Clin Exp Nephrol. 2013;17(1):1–2.
44. Williamson JD, Supiano MA, Pajewski NM. Intensive vs standard blood pressure control for older adults: reply. JAMA. 2016;316(18):1923.